MA53986A - Traitement de maladies neurologiques avec du zilucoplan - Google Patents

Traitement de maladies neurologiques avec du zilucoplan

Info

Publication number
MA53986A
MA53986A MA053986A MA53986A MA53986A MA 53986 A MA53986 A MA 53986A MA 053986 A MA053986 A MA 053986A MA 53986 A MA53986 A MA 53986A MA 53986 A MA53986 A MA 53986A
Authority
MA
Morocco
Prior art keywords
zilucoplan
treatment
neurological diseases
neurological
diseases
Prior art date
Application number
MA053986A
Other languages
English (en)
Inventor
Petra Duda
Ramin Farzaneh-Far
Zhong Ma
Alonso Ricardo
Evan Thackaberry
Nanqun Zhu
Original Assignee
Ra Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ra Pharmaceuticals Inc filed Critical Ra Pharmaceuticals Inc
Publication of MA53986A publication Critical patent/MA53986A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/322—Retractable needles, i.e. disconnected from and withdrawn into the syringe barrel by the piston
    • A61M5/3234—Fully automatic needle retraction, i.e. in which triggering of the needle does not require a deliberate action by the user
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
MA053986A 2018-10-22 2019-10-22 Traitement de maladies neurologiques avec du zilucoplan MA53986A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862748659P 2018-10-22 2018-10-22
US201862777524P 2018-12-10 2018-12-10
US201962815575P 2019-03-08 2019-03-08
US201962837974P 2019-04-24 2019-04-24
US201962844388P 2019-05-07 2019-05-07
US201962899864P 2019-09-13 2019-09-13

Publications (1)

Publication Number Publication Date
MA53986A true MA53986A (fr) 2022-01-26

Family

ID=68696508

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053986A MA53986A (fr) 2018-10-22 2019-10-22 Traitement de maladies neurologiques avec du zilucoplan

Country Status (13)

Country Link
US (1) US20220133841A1 (fr)
EP (1) EP3870221A1 (fr)
JP (1) JP2022508952A (fr)
KR (1) KR20210080390A (fr)
CN (1) CN113226368A (fr)
AU (1) AU2019365804A1 (fr)
BR (1) BR112021007083A2 (fr)
CA (1) CA3115828A1 (fr)
MA (1) MA53986A (fr)
MX (1) MX2021004366A (fr)
SG (1) SG11202103972SA (fr)
TW (1) TW202034943A (fr)
WO (1) WO2020086506A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
CA3150594A1 (fr) 2019-09-12 2021-03-18 Ra Pharmaceuticals, Inc. Traitement de maladies neurologiques avec des inhibiteurs de complement
WO2023215586A1 (fr) 2022-05-05 2023-11-09 UCB Biopharma SRL Traitement de la myasthénie grave avec zilucoplan
WO2023215587A1 (fr) 2022-05-05 2023-11-09 UCB Biopharma SRL Traitement de la myasthénie grave avec du zilucoplan

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007293013B2 (en) * 2006-09-05 2013-06-27 Alexion Pharmaceuticals, Inc. Method and compositions for the treatment of antibody mediated neuropathies
EP2331561A4 (fr) 2008-09-03 2013-02-27 Xenome Ltd Bibliothèques de conjugués peptidiques et leurs méthodes de fabrication
EP3973994A1 (fr) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation d'activité complémentaire
ES2900998T3 (es) 2015-01-28 2022-03-21 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento

Also Published As

Publication number Publication date
EP3870221A1 (fr) 2021-09-01
TW202034943A (zh) 2020-10-01
MX2021004366A (es) 2021-08-16
CA3115828A1 (fr) 2020-04-30
AU2019365804A1 (en) 2021-05-20
KR20210080390A (ko) 2021-06-30
WO2020086506A1 (fr) 2020-04-30
CN113226368A (zh) 2021-08-06
SG11202103972SA (en) 2021-05-28
US20220133841A1 (en) 2022-05-05
BR112021007083A2 (pt) 2021-08-03
JP2022508952A (ja) 2022-01-19

Similar Documents

Publication Publication Date Title
MA53986A (fr) Traitement de maladies neurologiques avec du zilucoplan
MA49767A (fr) Conjugués de cytokine pour le traitement de maladies auto-immunes
IL262608A (en) Combined treatment of eye disorders and inflammatory diseases
IL262277A (en) Treatment of eye diseases with fully human fab with post-translational modification against vegf
IL273403A (en) Treatment of eye diseases with FAB against fully humanized post-translationally modified VEGF
IL276383B1 (en) Treatment of ophthalmological diseases
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
MA49664A (fr) Combinaisons d'un dérivé de 4-pyrimidinesulfamide avec des principes actifs pour le traitement de maladies liées à l'endothéline
MA46061A (fr) Traitement ascaroside de maladies auto-immunes et inflammatoires
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA47503A (fr) Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
MA44126A (fr) Méthodes de traitement de maladies et troubles pulmonaires
MA42930A (fr) Traitement de maladies neurodégénératives
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
ZA201903003B (en) Treatment of neurological diseases
IL268357A (en) Photoreceptor cells for the treatment of retinal diseases
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
MA52495A (fr) Nouveau traitement de maladies pulmonaires interstitielles
FR3017298B1 (fr) Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
MA53817A (fr) Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
MA41462A (fr) Méthode de traitement de maladies
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
IL289405A (en) Personalized treatment of eye diseases